Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

TTI-101

Generic Name: TTI-101

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₁NO_₅S

CAS Number: 432001-19-9

Unique Ingredient Identifier: KZ3DLD11RQ

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Trial of Radiotherapy in Combination with TTI-101 in Patients with Borderline Resectable Pancreatic Cancer

Phase 1

Suspended

Posted: 2023/11/21

Sponsor:University of Colora...

ID:NCT06141031

Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck

Early Phase 1

Not yet recruiting

Posted: 2023/05/06

Sponsor:M.D. Anderson Cancer...

ID:NCT05845307

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Phase 2

Active, not recruiting

Posted: 2023/01/05

Sponsor:

Tvardi Therapeutics,...

ID:NCT05671835

Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1

Not yet recruiting

Posted: 2022/12/30

Sponsor:M.D. Anderson Cancer...

ID:NCT05668949

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Phase 1

Recruiting

Posted: 2022/07/01

Sponsor:

Tvardi Therapeutics,...

ID:NCT05440708

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Tvardi Therapeutics Completes Merger with Cara, Advances STAT3 Inhibitor Programs for Fibrosis-Driven Diseases

a month ago

Tvardi Therapeutics has completed its merger with Cara Therapeutics, creating a Nasdaq-listed company focused on developing STAT3 inhibitors for fibrosis-driven diseases, with shares trading under the ticker "TVRD."

TTI-101 Shows Promise in Advanced Cancer Treatment by Targeting STAT3

5 months ago

A Phase 1 trial of TTI-101, a novel oral STAT3 inhibitor, demonstrates manageable safety and encouraging anti-tumor activity in patients with advanced metastatic cancer.

Tvardi Therapeutics to Present Phase 1 Trial Data of STAT3 Inhibitor TTI-101 at ASCO 2023

2 years ago

Tvardi Therapeutics, Inc. is set to present clinical results from the Phase 1 study of TTI-101, a STAT3 inhibitor, at the ASCO 2023 annual meeting. The study focuses on the safety, tolerability, and clinical activity of TTI-101 monotherapy in patients with advanced solid tumors.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy